TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency

Trial Profile

TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Rucaparib (Primary) ; Abiraterone acetate; Docetaxel; Enzalutamide
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TRITON3
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 08 Sep 2017 Trial design of two studies (TRITON2 and TRITON3) presented at the 42nd European Society for Medical Oncology Congress.
    • 30 Aug 2017 According to a Clovis Oncology media release, trial design the study will be presented at European Society for Medical Oncology 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top